Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce F Liu

Showing results (101-110 of 105) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 105 results.
The Journal of Clinical Investigation|June 16, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotypeRebecca L Porter, Siyu Sun, Micayla N Flores, et al.
The Journal of Clinical Investigation|July 7, 2026
PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancerJie Hao, Bose Kochupurakkal, Timothy B Branigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Medicine|June 24, 2020
A single-cell landscape of high-grade serous ovarian cancerBenjamin Izar, Itay Tirosh, Elizabeth H Stover, et al.
Pageof 11

Showing results (101-110 of 105) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 105 results.
The Journal of Clinical Investigation|June 16, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotypeRebecca L Porter, Siyu Sun, Micayla N Flores, et al.
The Journal of Clinical Investigation|July 7, 2026
PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancerJie Hao, Bose Kochupurakkal, Timothy B Branigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Nature Medicine|June 24, 2020
A single-cell landscape of high-grade serous ovarian cancerBenjamin Izar, Itay Tirosh, Elizabeth H Stover, et al.
Pageof 11